NCT06465693Active, not recruiting
Personalized Nutrition Therapy Using Continuous Glucose Monitoring to Improve Outcomes in Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 28 Jul 2025
Brief summary (registry, in English)
Nutrition guidelines state that multiple eating patterns are effective for type 2 diabetes and that therapy should be individualized. Yet many nutrition plans fail to account for interpersonal variability in blood glucose response to meals. This diminishes the ability of dietary interventions to optimize glycemic control and may lessen patient satisfaction, self--efficacy, and adherence. Continuous glucose monitoring (CGM) can facilitate behavior change in type 2 diabetes and has been associated with improved outcomes in nutrition intervention studies; this literature is limited by small study sample sizes and heterogeneity of study design and outcomes, and more data are needed. CGM could be a powerful tool for adapting a nutrition plan based on blood glucose response at an individual level. This study will test the use of CGM to personalize nutrition therapy compared to nutrition therapy alone (without CGM) for participants with type 2 diabetes who are not meeting glycemic treatment goals.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 8 (actual)
- First submitted
- 13 Jun 2024
- Start date
- May 2024
- Primary completion date
- Jul 2025
- Lead sponsor
- University of Minnesota
- Diseases
- Type 2 diabetes
- NCT number
- NCT06465693
What you commit to
- Study type: Interventional
- Participants enrolled: 8
- From May 2024 to the primary completion date, Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with insulin, sulfonylurea, or meglitinide
- Weight change \>5 pounds in the 3 months prior to enrollment
Other illness
- Type 1 diabetes
- Presence of any disease that would make adherence to the protocol difficult
Lab values
- Use of a nondiabetic medication affecting blood glucose (e.g. corticosteroid)
- Anemia (which affects HbA1c)
Other
- BMI \<25 kg/m2
- Estimated glomerular filtration rate \<60 ml/minute/1.73 m2
- Pregnant or breastfeeding
Who the study is looking for
- At least 18 years of age
- Have a previous diagnosis of type 2 diabetes
- HbA1c of 7.0 - 9.5%
- Stable medications for diabetes for at least 3 months prior to enrollment, with no plans to change medications or doses during the intervention period.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Minnesota Coordinator of this site? Confirm its status | Minneapolis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.